Ponatinib, a c-ABL1 inhibitor, is currently approved for CML and acute lymphoblastic leukemia (ALL) therapy, and it is also a fibroblast-macrophage colony-stimulating factor (FMSF)-like tyrosine kinase 3 (FLT3) inhibitor. This evidence concerns the gene FLT3 and acute lymphoblastic leukemia.